

12-1-2016

## Coexisting Cardiac and Hematologic Disorders.

Jordan E. Goldhammer  
*Thomas Jefferson University*

Benjamin A. Kohl  
*Thomas Jefferson University*

Follow this and additional works at: <https://jdc.jefferson.edu/anfp>

 Part of the [Anesthesiology Commons](#)

[Let us know how access to this document benefits you](#)

---

### Recommended Citation

Goldhammer, Jordan E. and Kohl, Benjamin A., "Coexisting Cardiac and Hematologic Disorders." (2016). *Department of Anesthesiology Faculty Papers*. Paper 32.  
<https://jdc.jefferson.edu/anfp/32>

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's [Center for Teaching and Learning \(CTL\)](#). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Department of Anesthesiology Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: [JeffersonDigitalCommons@jefferson.edu](mailto:JeffersonDigitalCommons@jefferson.edu).

**Title**

Coexisting Cardiac and Hematologic Disorders

**Authors**

Jordan E. Goldhammer, MD  
Assistant Professor  
Department of Anesthesiology  
Sidney Kimmel Medical College  
Thomas Jefferson University

Benjamin A. Kohl, MD  
Professor  
Department of Anesthesiology  
Sidney Kimmel Medical College  
Thomas Jefferson University

**Corresponding Author**

Jordan E. Goldhammer, MD  
Department of Anesthesiology  
Thomas Jefferson University  
111 South 11th St  
Gibbon Building, Suite 8280  
Philadelphia PA, 19107  
Phone: 215-955-6161  
Fax: 215-955-0677  
Email: [Jordan.Goldhammer@Jefferson.edu](mailto:Jordan.Goldhammer@Jefferson.edu)

## **Manuscript Body**

### **Introduction**

Patients with concomitant cardiac and hematologic disorders presenting for non-cardiac surgery are challenging to even the most experienced anesthesiologists. Understanding the rationale of a patient's therapy and calculating the risk of changing this regimen in the perioperative period is essential. This chapter will focus on several of the more common disorders and will discuss strategies to optimize care in patients with coexisting cardiac and hematologic disease.

### **Sickle Cell Anemia**

Sickle cell disease results from a variety of inherited genetic mutations in the hemoglobin beta (HBB) gene resulting in defective beta-globin synthesis and culminating in attenuated oxygen transport. One particular HBB gene mutation produces an altered beta-globin molecule known as hemoglobin S (Hb S). Two genotypes are expressed: 1) heterozygous (sickle cell trait) or 2) homozygous (sickle cell disease).

### **Sickle Cell Disease**

The clinical characteristics of sickle cell disease (SCD) include anemia and recurrent vaso-occlusive crisis that commonly affect the cardiac, pulmonary, renal, neurologic, and musculoskeletal systems. A growing body of literature suggests, within the natural history of SCD, cardiovascular disease may play a role in disease progression and early mortality<sup>1</sup>. In a cohort study of 240 patients with SCD,

cardiopulmonary compromise resulted in 39.5% of the recorded mortalities <sup>1</sup> .

Causes of cardiovascular mortality include myocardial ischemia, malignant arrhythmia, heart failure, and pulmonary hypertension.

Chronic anemia of SCD results in an increased cardiac output and intravascular volume retention to maintain oxygen delivery. Increased intravascular volume results in left ventricular dilation and eccentric hypertrophy. Arrhythmias, including atrial fibrillation, supraventricular tachycardia, and ventricular fibrillation frequently arise secondary to chronic volume overload and have been linked to cardiovascular mortality. Baseline QT prolongation has been reported in 38% of pediatric and young adult patients with SCD <sup>2</sup> . Left ventricular systolic function is typically preserved; however, myocardial hypertrophy and increased LV mass lead to diastolic dysfunction and increased LV filling pressure. Diastolic dysfunction has been associated with increased age, hypertension, and renal failure and has been identified as an independent risk factors for mortality in patients with SCD <sup>3,4</sup> .

Chronic hemolytic anemia results in release of free hemoglobin and other red blood cell intracellular enzymes that inhibit nitric oxide signaling pathways causing vasoconstriction <sup>3</sup> . Within the pulmonary vasculature, this mechanism is responsible for the development of primary pulmonary hypertension. Pulmonary hypertension, either secondary to volume overload and underlying diastolic heart failure, or as a primary pathology, is encountered in up to 60% of adult patients with SCD and contributes to early cardiovascular mortality <sup>5,6</sup> . Increased pulmonary

pressures should be treated aggressively in order to reduce right ventricular afterload and mitigate right ventricular failure.

Myocardial infarction in the SCD population results from microvascular vessel occlusion and thus coronary angiography is typically normal<sup>7</sup>. Supportive care including hydration, supplemental oxygen therapy, and blood transfusion may be initiated; however, exchange transfusion appears to be the definitive therapy during severe coronary ischemia. Exchange transfusion to replace Hb S with normal adult hemoglobin (Hb A) results in reduced microvascular viscosity, inhibition of the inflammatory cascade, and restoration of the intrinsic nitric oxide pathway<sup>8</sup>.

Patients with SCD frequently present for anesthesia and surgery. An understanding of the pathophysiology of this disease is critical to provide optimal care. Perioperative transfusion has been shown to decrease both vaso-occlusive and cardiac complications in patients undergoing low and medium risk surgery<sup>9</sup>. A transfusion threshold of 10 g/dl is generally recommended; however, the need for exchange transfusion and reduced Hb S level is less clear. Conservative transfusion (maintain Hgb of 10 g/dl), compared to aggressive transfusion (maintain Hgb  $\geq$ 10 g/dl *and* exchange transfusion to decrease Hb S <30%), results in 50% less blood administration and similar complication rates in low to moderate risk surgery<sup>10</sup>. Major cardiac surgery has been undertaken utilizing both aggressive exchange transfusion and conservative transfusion protocols with similar complication rates<sup>11,12</sup>.

In patients with SCD and co-existing cardiac disease, a conservative transfusion strategy to a target Hgb of 10 g/dl should be undertaken. Although

aggressive exchange transfusion may significantly reduce Hb S content, the risk of blood product administration and volume overload must be reconciled in this population. Those with underlying pulmonary hypertension, diastolic dysfunction, or cardiomyopathy, require titrated transfusion and volume administration to avoid exacerbation of right heart failure or malignant arrhythmias.

### **Sickle Cell Trait**

Sickle cell trait (SCT) is a carrier state of the Hb S mutation occurring in 1.6% of the US population<sup>13</sup>. Patients with SCT have a higher incidence of urologic disease including: hematuria, chronic kidney disease, and renal medullary carcinoma. A small percentage of these patients may display some vaso-occlusive phenomenon; however, cardiovascular manifestations of SCD are absent and life expectancy is typically normal. Patients with SCT presenting for surgery and anesthesia should be managed according to their underlying co-morbidities; no discrete management due to their status as a SCT carrier is indicated.

### **Anemia of Chronic Disease**

Anemia of chronic disease (ACD) is typically a mild anemia with a normocytic, normochromic profile primarily due to reduced red blood cell production. ACD (Hgb <12 g/dl for female, Hgb < 13 g/dl for male) is associated with increased age, diabetes, renal insufficiency, chronic immune activation, and cardiac disease; present in 10% of those with coronary disease and as high as 79% of patients with advanced heart failure<sup>14-16</sup>. In the general population,

observational studies have shown the non-inferiority of restrictive transfusion protocols (compared with more liberal targets) in the perioperative period; however, less robust clinical data exists for patients with perioperative anemia and advanced cardiac disease. One study evaluated the natural history of anemia, following a subset of anemic patients who refused blood transfusion in the perioperative period. In those patients with co-existing cardiac disease, the refusal of blood products was associated with an increased risk of death.<sup>17</sup> A randomized pilot trial of 110 anemic patients with acute coronary syndrome or stable angina undergoing cardiac catheterization revealed greater than twice the risk of myocardial infarction, unscheduled revascularization, or death within 30 days when treated with a restrictive (transfusion for symptomatic anemia or Hbg <8 g/dl) transfusion protocol<sup>18</sup>. However, recent registry data further obfuscates the decision whether or not to transfuse these patients; data have shown an increased risk of cardiovascular morbidity with as little as one unit of red blood cell transfusion during the perioperative period<sup>19</sup>. In support of restrictive transfusion practices, a post-hoc analysis of a subset of 796 patients with known coronary disease from a large, randomized, controlled trial of hip fracture patients randomized to restrictive (Hbg <8 mg/dl or symptomatic anemia) or liberal (Hbg < 10 mg/dl) transfusion found similar 30-day mortality rates between the two groups<sup>20,21</sup>. In addition, subgroup analysis of patients with cardiovascular disease from the Transfusion Requirement in Critical Care (TRICC) trial found no difference in 30 day, 60 day, ICU, or in-hospital mortality when randomized to restrictive (Hbg 7.0-9.0 g/dl) or liberal transfusion (Hbg 10.0-12.0 g/dl)<sup>22,23</sup>. Even in the setting of

acute coronary syndrome liberal transfusion is not without risk, as a greater degree of complications related to heart failure has been observed in anemic patients<sup>24</sup>.

While patients with ongoing ischemia may benefit from transfusion to restore myocardial oxygen delivery, the treatment of anemia in those patients with CAD or severe heart failure should be approached in a methodical fashion based upon underlying symptomatology, with a focus on end-organ perfusion and oxygenation. Physical exam (mental status, urine output), lab monitoring (arterial lactate, acid/base status), and physiologic monitoring (heart rate, blood pressure, cardiac index) should all be used to optimize goal directed transfusion therapy in this complex patient population.

## **Platelet Abnormalities**

### **Thrombocytosis**

Essential thrombocytosis (ET) is a rare disorder affecting approximately 3/1,000,000 patients and is associated with both thrombosis and hemorrhage. Acute coronary thrombosis may occur in up to 9.4% of patients with ET<sup>25</sup>. Age, smoking, hypertension, hyperlipidemia, history of thrombotic events, duration of thrombocytosis, and platelet count  $>1,500,000 /\mu\text{L}$  are associated with increased thrombotic risk<sup>26,27</sup>. Patients with existing risk factors and a history of occlusive CAD requiring stents or open revascularization should be treated aggressively with a platelet lowering regimen to decrease the likelihood of stent thrombosis or



recurrent thrombotic occlusion. Hydroxyurea has been utilized in both ET and polycythemia vera; and, when compared to control, decreases both platelet count and thrombotic events in those patients at high risk for thrombotic complications from thrombocytosis<sup>28</sup>. Strategies to decrease platelet count, generally below 600,000/ $\mu$ L, have been proven to reduce thrombosis<sup>27,28</sup>. Aspirin and hydroxyurea should be continued throughout the perioperative period in patients with ET. High-risk patients, especially those with a history of CAD, should be aggressively managed with hydroxyurea to a target platelet count <600,000/ $\mu$ L in order to decrease the incidence of thrombotic complications. If signs of acute coronary syndrome develop, emergent cardiac catheterization is indicated, as the inciting lesion should be assumed to be occlusive coronary thrombosis until proven otherwise.

### **Idiopathic Thrombotic Purpura**

Immune thrombocytopenic purpura (ITP) is an acquired deficiency of both platelet count and function. ITP may be classified as either primary (idiopathic) or secondary (typically due to infection such as hepatitis C, human immunodeficiency virus, or other autoimmune syndromes such as systemic lupus erythematosus). Thrombocytopenia in ITP is caused by antibodies to platelet antigens resulting in decreased platelet lifespan and impaired platelet production. Circulating platelets are often large and immature, increasing the risk of thrombotic events<sup>30</sup>. Although rare, coexisting ITP and CAD has been managed by either traditional coronary artery bypass or percutaneous intervention; however, both pose significant management dilemmas. Open revascularization is associated with increased bleeding risk due to thrombocytopenia, whereas stent implantation is complicated

by the need for post-intervention antiplatelet therapy. IVIG and steroid therapy, coupled with perioperative platelet transfusion, has been used with acceptable results; however, in those with ITP both open revascularization and percutaneous intervention are associated with a moderate increase in bleeding<sup>31</sup>. The preponderance of percutaneous interventions in these patients have utilized bare metal stents in an effort to limit the duration of post-intervention antiplatelet therapy<sup>31,32</sup>. A critical assessment of the balance of thrombosis prevention and bleeding risk must be achieved. Aspirin and clopidogrel have been used successfully; however, GP IIb/IIIa inhibitors are associated with uncontrolled bleeding and should be avoided<sup>33,34</sup>. Post intervention antiplatelet agents can be used until the platelet count falls below 20,000/ $\mu$ L or clinical bleeding occurs.

### **Thrombotic Thrombocytopenic Purpura**

Thrombotic thrombocytopenic purpura (TTP) is a rare and often fatal disorder characterized by thrombocytopenia, hemolytic anemia, renal failure, and mental status changes. The incidence of TTP in the general population is approximately 3.7/1,000,000 however, following percutaneous coronary intervention the incidence is much higher due to antiplatelet induced TTP<sup>35</sup>. TTP has been reported in be 1/4,814 patients treated with ticlopidine<sup>36</sup>. Clopidogrel has a safer side effect profile, however reports of TTP following administration exist<sup>37</sup>. Early diagnosis and treatment of antiplatelet induced TTP is essential as mortality approaches 67% without prompt plasmapheresis<sup>36</sup>.

### **Anticoagulation for Cardiac Devices**

## Artificial Valves

Artificial heart valves may be implanted for acute or chronic valvular dysfunction, resulting in stenotic or regurgitant heart disease. Two main classes of devices are mechanical valves and bioprosthetic valves. Bioprosthetic valves may be either a cadaveric homograft or a xenograft composed of porcine or bovine pericardium mounted on a stent. Although the lifespan of bioprosthetic valves is generally reduced compared with mechanical valves, use of the tissue material precludes the need for anticoagulation unless special circumstances arise. In contrast, mechanical valves are composed of pyrolytic carbon and last an indefinite period of time. However, due to the high rate of thrombosis, mechanical valves require aggressive long-term anticoagulation. According to the AHA/ACC guidelines, patients with a mechanical valve in the mitral position should be anticoagulated to a target median INR of 3.0<sup>38</sup>. Due to an accelerated transvalvular flow pattern, the target median INR of a valve in the aortic position in those without thrombotic risk factors (atrial fibrillation, left ventricular dysfunction, hypercoagulable state, previous thrombotic event) is 2.5<sup>38</sup>. Although major guidelines differ in their specific recommendation, aspirin, in addition to warfarin, is generally recommended in those without increased bleeding risk<sup>38-40</sup>.

Anticoagulation therapy in preparation for non-cardiac surgery must take into account both the bleeding risk of surgery and the thrombotic risk of abruptly discontinuing anticoagulation. In general, minor dental or cutaneous procedures may be accomplished without interruption of anticoagulation; however, if the surgical site is not amenable to local hemostasis or major surgery is planned, a

preoperative INR <1.5 is desirable. Warfarin should be discontinued 5-6 days prior to surgical intervention and anticoagulant bridging with a heparin analogue is indicated.

On rare occasions, patients on chronic anticoagulation for mechanical heart valves may suffer from warfarin overdose. This is typically manifest by an elevated INR and frequently results from medication mismanagement or a change in absorption pharmacokinetics. If no significant bleeding occurs, warfarin can be held and oral vitamin K administered until target INR is reached. In those with severe bleeding, prothrombin complex concentrates or fresh frozen plasma may be used to expeditiously normalize the INR. Complications from severe bleeding generally outweigh the risk of valve thrombosis. Anticoagulation can be safely interrupted for 7-14 days even in those at high risk for thromboembolic events <sup>41</sup>.

Pregnant patients with mechanical heart valves pose multiple challenges. Parturients are hypercoagulable due to changes in blood viscosity, decreased fibrinolysis, and upregulation of clotting factors. All pregnant patients with artificial heart valves should be deemed "high risk" as the percentage of pregnancies ending with both a live mother and child is approximately 81% <sup>42</sup>. Adequate anticoagulation to prevent mechanical valve thrombosis must be balanced against the risks of bleeding and teratogenicity of the anticoagulant. In a large registry series 4.5% of such patients experienced mechanical valve thrombosis with half of the events occurring in the first trimester <sup>42</sup>. Anticoagulation regimens in the first trimester remain a matter of debate, as warfarin has been proven to be superior to heparin analogues for thrombosis prophylaxis; however concerns for teratogenicity,

miscarriage (<24 weeks), and late fetal death (>24 weeks) exist <sup>42</sup>. Multiple medication regimens have been studied including warfarin, unfractionated heparin, and low molecular weight heparin. Current guidelines suggest either administration of low dose (<5mg/day) warfarin or discontinuation of warfarin in the first trimester <sup>38</sup>. If resumed, complete discontinuation of warfarin is indicated after 36 weeks in preparation for delivery. Anticoagulant coverage can be provided during warfarin-free periods; or, alternatively maintained for the duration of pregnancy with unfractionated or low molecular weight heparin. Regardless of the medication choice; pregnancy in this patient population is best managed by a multi-disciplinary team and the risk/benefit of anticoagulant medications must be discussed with the patient.

### **Ventricular Assist Device**

A left ventricular assist device (LVAD) can be utilized in three clinical scenarios: 1) acute ventricular failure as a bridge to recovery; 2) chronic ventricular failure as a bridge to heart transplantation; or 3) for permanent implantation in those not suitable for heart transplantation. All LVADs fall into one of two physiologic categories based on how blood is circulated through the device: pulsatile or non-pulsatile. Non-pulsatile, or continuous flow, LVADs are smaller in size, operate silently, and have greater durability when compared to pulsatile flow LVADs <sup>43</sup>.

Careful consideration of the anticoagulation status in patients with an LVAD is important for optimal management. Thrombus formation within the device, reported to occur between 2-12% at 24 months, can lead to embolic events or LVAD

failure<sup>44</sup>. LVAD patients are anticoagulated with a regimen consisting of anti-platelet agents and warfarin. Target median INR varies between centers from 2.0-2.5<sup>43</sup>.

Major bleeding may occur in patients with an LVAD secondary to aggressive anticoagulation, hemolysis, and down regulation of clotting factors. Although the etiology is not yet completely understood, many continuous-flow LVADs cause reduced levels of von Willebrand factor, which may further increase the risk of bleeding. The need to reverse or withhold anticoagulation depends on the severity and location of hemorrhage. Prothrombin complex concentrates or fresh frozen plasma can be administered to reverse warfarin. Anticoagulation therapy should immediately resume when the risk of thrombosis outweighs the risk of further bleeding.

The extended lifespan of new generation LVADs, coupled with their use for destination therapy, has resulted in a large proportion of these patients presenting for elective, non-cardiac surgery. In patients without additional indication for anticoagulation (atrial fibrillation, left ventricular thrombus) cessation of warfarin 5-6 days before surgery and continuation of aspirin has reduced the need for perioperative blood transfusion without an increase in thrombosis<sup>45</sup>. In patients at high risk for thrombosis, anticoagulation bridging with a heparin analogue is indicated. Warfarin anticoagulation can be safely resumed in the postoperative period when bleeding risk has subsided.

## Heart Failure with Reduced Ejection Fraction

Heart failure is associated with significant morbidity and mortality from thromboembolic events leading to stroke, myocardial infarction, deep vein thrombosis, and pulmonary embolus. The pathophysiology of thromboembolism in heart failure is primarily related to blood stasis within the left ventricle, endothelial dysfunction, and increased platelet activation. The addition of anticoagulant and/or antithrombotic therapy in those with coexisting atrial fibrillation or previous thromboembolic event is recommended; however, anticoagulant therapy for patients in sinus rhythm with reduced ejection fraction is less clear. Multiple randomized controlled trials have compared the use of warfarin, aspirin, and clopidogrel in this patient population with conflicting results<sup>46-48</sup>. Aspirin has been associated with increased risk for hospitalization and gastrointestinal bleeding; however, this may be due to an as yet undefined interaction with ACE inhibitors<sup>49</sup>. Baseline warfarin use has been associated with a reduction in all-cause mortality and acute coronary syndrome; however, the rate of major bleeding is increased when compared with aspirin or clopidogrel<sup>49</sup>. Antiplatelet and antithrombotic use in patients with normal sinus rhythm and reduced ejection fraction should be dictated based upon underlying co-morbidities and heart failure pathology. Although controversial, aspirin may be of benefit in patients with underlying coronary disease and heart failure secondary to ischemic cardiomyopathy. Alternatively, warfarin can be used to decrease thrombosis risk and improve intermediate morbidity and mortality in those with reduced ejection fraction and

normal cardiac rhythm.; however, therapy should be reserved for only patients at low risk for bleeding complications.

## **Conclusion**

Patients with concomitant hematologic and cardiac issues represent challenges to everyone involved in their perioperative care. An understanding of the pertinent pathophysiology, the appropriate therapy and the risks are essential. In the end, management decisions should be based on a thoughtful discussion with other involved providers and a balanced approach that explicitly addresses the risk and benefit of each intervention.



## References

1. Fitzhugh CD, Lauder N, Jonassaint JC, et al. Cardiopulmonary complications leading to premature deaths in adult patients with sickle cell disease. *Am J Hematol*. 2010;85(1):36-40. doi: 10.1002/ajh.21569 [doi].
2. Liem RI, Young LT, Thompson AA. Prolonged QTc interval in children and young adults with sickle cell disease at steady state. *Pediatr Blood Cancer*. 2009;52(7):842-846. doi: 10.1002/pbc.21973 [doi].
3. Gladwin MT, Sachdev V. Cardiovascular abnormalities in sickle cell disease. *J Am Coll Cardiol*. 2012;59(13):1123-1133. doi: 10.1016/j.jacc.2011.10.900 [doi].
4. Sachdev V, Machado RF, Shizukuda Y, et al. Diastolic dysfunction is an independent risk factor for death in patients with sickle cell disease. *J Am Coll Cardiol*. 2007;49(4):472-479. doi: S0735-1097(06)02776-8 [pii].
5. Vichinsky EP. Pulmonary hypertension in sickle cell disease. *N Engl J Med*. 2004;350(9):857-859. doi: 10.1056/NEJMp038250 [doi].
6. Voskaridou E, Christoulas D, Terpos E. Sickle-cell disease and the heart: Review of the current literature. *Br J Haematol*. 2012;157(6):664-673. doi: 10.1111/j.1365-2141.2012.09143.x [doi].
7. Pavlu J, Ahmed RE, O'Regan DP, Partridge J, Lefroy DC, Layton DM. Myocardial infarction in sickle-cell disease. *Lancet*. 2007;369(9557):246. doi: S0140-6736(07)60114-7 [pii].

8. Pannu R, Zhang J, Andraws R, Armani A, Patel P, Mancusi-Ungaro P. Acute myocardial infarction in sickle cell disease: A systematic review. *Crit Pathw Cardiol.* 2008;7(2):133-138. doi: 10.1097/HPC.0b013e3181668ac3 [doi].
9. Howard J, Malfroy M, Llewelyn C, et al. The transfusion alternatives preoperatively in sickle cell disease (TAPS) study: A randomised, controlled, multicentre clinical trial. *Lancet.* 2013;381(9870):930-938. doi: 10.1016/S0140-6736(12)61726-7 [doi].
10. Vichinsky EP, Haberkern CM, Neumayr L, et al. A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. the preoperative transfusion in sickle cell disease study group. *N Engl J Med.* 1995;333(4):206-213. doi: 10.1056/NEJM199507273330402 [doi].
11. Edwin F, Aniteye E, Tettey M, et al. Hypothermic cardiopulmonary bypass without exchange transfusion in sickle-cell patients: A matched-pair analysis. *Interact Cardiovasc Thorac Surg.* 2014;19(5):771-776. doi: 10.1093/icvts/ivu249 [doi].
12. Yousafzai SM, Ugurlucan M, Al Radhwan OA, Al Otaibi AL, Canver CC. Open heart surgery in patients with sickle cell hemoglobinopathy. *Circulation.* 2010;121(1):14-19. doi: 10.1161/CIRCULATIONAHA.109.882464 [doi].
13. Ojodu J, Hulihan MM, Pope SN, Grant AM, Centers for Disease Control and Prevention (CDC). Incidence of sickle cell trait--united states, 2010. *MMWR Morb Mortal Wkly Rep.* 2014;63(49):1155-1158. doi: mm6349a3 [pii].

14. Boyd CM, Leff B, Wolff JL, et al. Informing clinical practice guideline development and implementation: Prevalence of coexisting conditions among adults with coronary heart disease. *J Am Geriatr Soc*. 2011;59(5):797-805. doi: 10.1111/j.1532-5415.2011.03391.x [doi].
15. Felker GM, Adams KF, Jr, Gattis WA, O'Connor CM. Anemia as a risk factor and therapeutic target in heart failure. *J Am Coll Cardiol*. 2004;44(5):959-966. doi: 10.1016/j.jacc.2004.05.070 [doi].
16. Silverberg DS, Wexler D, Blum M, et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. *J Am Coll Cardiol*. 2000;35(7):1737-1744. doi: S0735-1097(00)00613-6 [pii].
17. Carson JL, Duff A, Poses RM, et al. Effect of anaemia and cardiovascular disease on surgical mortality and morbidity. *Lancet*. 1996;348(9034):1055-1060. doi: S0140-6736(96)04330-9 [pii].
18. Carson JL, Brooks MM, Abbott JD, et al. Liberal versus restrictive transfusion thresholds for patients with symptomatic coronary artery disease. *Am Heart J*. 2013;165(6):964-971.e1. doi: 10.1016/j.ahj.2013.03.001 [doi].
19. Whitlock EL, Kim H, Auerbach AD. Harms associated with single unit perioperative transfusion: Retrospective population based analysis. *BMJ*. 2015;350:h3037. doi: 10.1136/bmj.h3037 [doi].

20. Carson JL, Terrin ML, Noveck H, et al. Liberal or restrictive transfusion in high-risk patients after hip surgery. *N Engl J Med*. 2011;365(26):2453-2462. doi: 10.1056/NEJMoa1012452 [doi].
21. Kansagara D, Dyer E, Englander H, Fu R, Freeman M, Kagen D. Treatment of anemia in patients with heart disease: A systematic review. *Ann Intern Med*. 2013;159(11):746-757. doi: 10.7326/0003-4819-159-11-201312030-00007 [doi].
22. Hebert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. transfusion requirements in critical care investigators, canadian critical care trials group. *N Engl J Med*. 1999;340(6):409-417. doi: 10.1056/NEJM199902113400601 [doi].
23. Hebert PC, Yetisir E, Martin C, et al. Is a low transfusion threshold safe in critically ill patients with cardiovascular diseases? *Crit Care Med*. 2001;29(2):227-234.
24. Cooper HA, Rao SV, Greenberg MD, et al. Conservative versus liberal red cell transfusion in acute myocardial infarction (the CRIT randomized pilot study). *Am J Cardiol*. 2011;108(8):1108-1111. doi: 10.1016/j.amjcard.2011.06.014 [doi].
25. Rossi C, Randi ML, Zerbinati P, Rinaldi V, Girolami A. Acute coronary disease in essential thrombocythemia and polycythemia vera. *J Intern Med*. 1998;244(1):49-53.

26. Griesshammer M. Risk factors for thrombosis and bleeding and their influence on therapeutic decisions in patients with essential thrombocythemia. *Semin Thromb Hemost.* 2006;32(4 Pt 2):372-380. doi: 10.1055/s-2006-942758 [doi].
27. Cortelazzo S, Viero P, Finazzi G, D'Emilio A, Rodeghiero F, Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. *J Clin Oncol.* 1990;8(3):556-562.
28. Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. *N Engl J Med.* 1995;332(17):1132-1136. doi: 10.1056/NEJM199504273321704 [doi].
29. Squizzato A, Romualdi E, Passamonti F, Middeldorp S. Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia. *Cochrane Database Syst Rev.* 2013;4:CD006503. doi: 10.1002/14651858.CD006503.pub3 [doi].
30. Sarpatwari A, Bennett D, Logie JW, et al. Thromboembolic events among adult patients with primary immune thrombocytopenia in the united kingdom general practice research database. *Haematologica.* 2010;95(7):1167-1175. doi: 10.3324/haematol.2009.018390 [doi].
31. Russo A, Cannizzo M, Ghetti G, et al. Idiopathic thrombocytopenic purpura and coronary artery disease: Comparison between coronary artery bypass grafting and percutaneous coronary intervention. *Interact Cardiovasc Thorac Surg.* 2011;13(2):153-157. doi: 10.1510/icvts.2011.271296 [doi].

32. Chan Wah Hak CM, Tan YO, Chan C. Coronary artery stenting in a patient with chronic immune thrombocytopenic purpura: A clinical conundrum. *BMJ Case Rep.* 2012;2012:10.1136/bcr-02-2012-5802. doi: 10.1136/bcr-02-2012-5802 [doi].
33. Mendez TC, Diaz O, Enriquez L, Baz JA, Fernandez F, Goicolea J. Severe thrombocytopenia refractory to platelet transfusions, secondary to abciximab readministration, in a patient previously diagnosed with idiopathic thrombocytopenic purpura. A possible etiopathogenic link. *Rev Esp Cardiol.* 2004;57(8):789-791. doi: 13064833 [pii].
34. Marques LG, Furukawa MK, Leitao TP, et al. Percutaneous transluminal coronary angioplasty in a patient with idiopathic thrombocytopenic purpura. *Arq Bras Cardiol.* 2005;84(4):337-339. doi: S0066-782X2005000400012 [pii].
35. Torok TJ, Holman RC, Chorba TL. Increasing mortality from thrombotic thrombocytopenic purpura in the united states--analysis of national mortality data, 1968-1991. *Am J Hematol.* 1995;50(2):84-90.
36. Steinhubl SR, Tan WA, Foody JM, Topol EJ. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT investigators. evaluation of platelet IIb/IIIa inhibitor for stenting. *JAMA.* 1999;281(9):806-810. doi: joc81467 [pii].
37. von Mach MA, Eich A, Weilemann LS, Munzel T. Subacute coronary stent thrombosis in a patient developing clopidogrel associated thrombotic thrombocytopenic purpura. *Heart.* 2005;91(2):e14. doi: 91/2/e14 [pii].

38. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: A report of the american college of cardiology/american heart association task force on practice guidelines. *Circulation*. 2014;129(23):e521-643. doi: 10.1161/CIR.0000000000000031 [doi].
39. Whitlock RP, Sun JC, Frenes SE, Rubens FD, Teoh KH, American College of Chest Physicians. Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. *Chest*. 2012;141(2 Suppl):e576S-600S. doi: 10.1378/chest.11-2305 [doi].
40. Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC), European Association for Cardio-Thoracic Surgery (EACTS), Vahanian A, et al. Guidelines on the management of valvular heart disease (version 2012). *Eur Heart J*. 2012;33(19):2451-2496. doi: 10.1093/eurheartj/ehs109 [doi].
41. Phan TG, Koh M, Wijidicks EF. Safety of discontinuation of anticoagulation in patients with intracranial hemorrhage at high thromboembolic risk. *Arch Neurol*. 2000;57(12):1710-1713. doi: noc00071 [pii].
42. van Hagen IM, Roos-Hesselink JW, Ruys TP, et al. Pregnancy in women with a mechanical heart valve: Data of the european society of cardiology registry of pregnancy and cardiac disease (ROPAC). *Circulation*. 2015;132(2):132-142. doi: 10.1161/CIRCULATIONAHA.115.015242 [doi].

43. Slaughter MS, Pagani FD, Rogers JG, et al. Clinical management of continuous-flow left ventricular assist devices in advanced heart failure. *J Heart Lung Transplant*. 2010;29(4 Suppl):S1-39. doi: 10.1016/j.healun.2010.01.011 [doi].
44. Baumann Kreuziger LM. Management of anticoagulation and antiplatelet therapy in patients with left ventricular assist devices. *J Thromb Thrombolysis*. 2015;39(3):337-344. doi: 10.1007/s11239-014-1162-6 [doi].
45. Morgan JA, Paone G, Nemeh HW, et al. Non-cardiac surgery in patients on long-term left ventricular assist device support. *J Heart Lung Transplant*. 2012;31(7):757-763. doi: 10.1016/j.healun.2012.02.023 [doi].
46. Massie BM, Collins JF, Ammon SE, et al. Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: The warfarin and antiplatelet therapy in chronic heart failure (WATCH) trial. *Circulation*. 2009;119(12):1616-1624. doi: 10.1161/CIRCULATIONAHA.108.801753 [doi].
47. Homma S, Thompson JL, Pullicino PM, et al. Warfarin and aspirin in patients with heart failure and sinus rhythm. *N Engl J Med*. 2012;366(20):1859-1869. doi: 10.1056/NEJMoa1202299 [doi].
48. Cokkinos DV, Haralabopoulos GC, Kostis JB, Toutouzas PK, HELAS investigators. Efficacy of antithrombotic therapy in chronic heart failure: The HELAS study. *Eur J Heart Fail*. 2006;8(4):428-432. doi: S1388-9842(06)00064-X [pii].



49. Prom R, Usedom JE, Dull RB. Antithrombotics in heart failure with reduced ejection fraction and normal sinus rhythm: An evidence appraisal. *Ann Pharmacother.* 2014;48(2):226-237. doi: 10.1177/1060028013511058 [doi].



